Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler
Piper Sandler analyst Joseph Catanzaro lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $7.50 from $10 and keeps a Neutral ...